Jasper Therapeutics (JSPR) grants director option for 7,500 shares
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. reported that director Judith Anne Shizuru received an automatic grant of a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, under the Non-Employee Director Compensation Policy. The option has a $0.63 exercise price, vests in full on July 31, 2027, and expires on July 31, 2036, leaving her with 7,500 options held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shizuru Judith Anne
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy F1 | 7,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy — 7,500 shares (Direct)
Footnotes (1)
- F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Key Figures
Stock options granted: 7,500 shares
Exercise price: $0.6300 per share
Vesting date: July 31, 2027
+2 more
5 metrics
Stock options granted
7,500 shares
Automatic grant to director on July 31, 2026
Exercise price
$0.6300 per share
Conversion or exercise price of the option
Vesting date
July 31, 2027
Option vests in full on first anniversary of grant
Expiration date
July 31, 2036
Option expiration date
Options held after grant
7,500 shares
Total derivative securities held directly following transaction
Key Terms
Non-Employee Director Compensation Policy, Stock Option (Right to Buy, Voting Common Stock, vest in full
4 terms
Non-Employee Director Compensation Policy financial
"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy"
Stock Option (Right to Buy financial
"security_title: Stock Option (Right to Buy"
Voting Common Stock financial
"underlying_security_title: Voting Common Stock"
vest in full financial
"which shall vest in full upon the first anniversary of the date of the grant"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Jasper Therapeutics (JSPR) report on July 31, 2026?
Jasper Therapeutics reported a grant of a stock option covering 7,500 shares of Voting Common Stock to director Judith Anne Shizuru on July 31, 2026, as a compensation award under the company’s non-employee director policy, not a market purchase or sale.
Who received the new stock option grant at Jasper Therapeutics (JSPR)?
Director Judith Anne Shizuru received the grant. She was awarded a stock option for 7,500 underlying shares of Voting Common Stock, reported as held directly after the transaction, reflecting compensation for her service on the board.
What are the exercise price, vesting, and expiration terms of the JSPR director option grant?
The stock option has a $0.63 per share exercise price, will vest in full on July 31, 2027, and will expire on July 31, 2036. These terms define when the director can exercise the option and how long the right remains outstanding.
Was the Jasper Therapeutics (JSPR) option grant made under a formal director compensation policy?
Yes. The option was granted automatically under the company’s Non-Employee Director Compensation Policy, which provides each non-employee director an annual option for 7,500 shares that vests on the first anniversary of the grant, subject to continued board service.
How many derivative securities does the JSPR director hold after this option grant?
Following the reported transaction, Judith Anne Shizuru holds 7,500 stock options directly. These options each relate to one share of Voting Common Stock and represent her derivative position reported in this filing after the compensation award.